McDermott Will & Schulte advised H.A.C. Pharma on acquisition from Roche of global (excluding United States) rights to ESBRIET (pirfenidone)

"McDermott Will & Schulte advised French pharmaceutical company H.A.C. Pharma in acquiring from Roche the worldwide (excluding the United States) rights to ESBRIET (pirfenidone) for the treatment of idiopathic pulmonary fibrosis in adults, strengthening H.A.C. Pharma's rare disease portfolio and international development."

McDermott Will & Schulte advised H.A.C. Pharma in its acquisition from Roche of the global (excluding the United States) rights to ESBRIET (pirfenidone). The transaction transfers to H.A.C. Pharma the worldwide rights, outside the United States, to ESBRIET (pirfenidone), a medicine intended for the treatment of idiopathic pulmonary fibrosis (IPF) in adults. This acquisition enables H.A.C. Pharma to reinforce its position in the rare disease market and to accelerate its international development. McDermott Will & Schulte represented client(s) H.A.C. Pharma with a team composed by: Health & Life Sciences Transaction: Emmanuelle Trombe (Partner), Anne-France Moreau (Partner), Caroline Noyrez (Associate) Corporate: Henri Pieyre de Mandiargues (Partner), Sophie Lafay (Counsel) Financing: Stanislas Chenu (Associate), Hugo Lamour (Associate), Clarisse de Roux (Associate) IP: Charles de Raignac (Counsel), Emie Paganon (Associate) Tax: Come de Saint Vincent (Partner), Pierre Henri de Laguiche (Associate)

McDermott Will & Schulte advised H.A.C. Pharma on acquisition from Roche of global (excluding United States) rights to ESBRIET (pirfenidone)

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads